Primary Hepatic Extra-gastrointestinal Stromal Tumors: Molecular Pathogenesis, Immunohistopathology, and Treatment

Gastrointestinal stromal tumors are the most common mesenchymal tumors of the gastrointestinal tract. They originate from the interstitial cells of Cajal and are usually found in extrahepatic gastrointestinal sites. However, a small subset are derived from the liver and are known as primary hepatic gastrointestinal stromal tumors (PHGIST). They have a poor prognosis and are historically difficult to diagnose. Our objective was to review and update the latest evidence-based knowledge concerning PHGIST, with a focus on epidemiology, etiology, pathophysiology, clinical presentation, histopathology, and treatment. These tumors are usually found incidentally, occur sporadically, and are associated with mutations of KIT and PDGFRA genes. PHGIST is a diagnosis of exclusion, as it has the same molecular, immunochemistry and histological appearance as gastrointestinal stromal tumors (GIST). Thus, imaging, such as positron emission tomography-computed tomography (PET-CT) must be used to rule out metastatic GIST before a diagnosis can be made. However, with mutation analysis and pharmacological advances, tyrosine kinase inhibitors are typically pursued with or without surgical intervention. Other potential treatments include transcatheter arterial chemoembolization and tumor ablation. However, these are typically considered palliative options. As there are only a limited number of publications regarding PHGIST, data concerning morbidity and mortality are not yet available. Immunohistopathology can help develop screening guidelines and evaluating resistance to treatment.

[1]  Chao-yong Shen,et al.  Primary hepatic gastrointestinal stromal tumor: A case series. , 2021, Asian journal of surgery.

[2]  M. R. Fernandes,et al.  Giant hepatic extra-gastrointestinal stromal tumor treated with cytoreductive surgery and adjuvant systemic therapy: A case report and review of literature , 2021, World journal of gastrointestinal surgery.

[3]  Xiaohui Qian,et al.  Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors , 2020, World journal of gastroenterology.

[4]  J. Ramia,et al.  Hepatic gastrointestinal stromal tumor: Systematic review of an exceptional location , 2019, World Journal of Meta-Analysis.

[5]  Liangliang Xu,et al.  Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion , 2019, Medicine.

[6]  P. Kim,et al.  Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors , 2018, Korean journal of radiology.

[7]  D. Park,et al.  Two staging systems for gastrointestinal stromal tumors in the stomach: which is better? , 2017, BMC Gastroenterology.

[8]  J. Blay,et al.  Gastrointestinal stromal tumors (GIST) presenting in the liver: Diagnostic, prognostic and therapeutic issues. , 2017, Clinics and research in hepatology and gastroenterology.

[9]  Aki Vehtari,et al.  Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial , 2017, JAMA oncology.

[10]  T. Maruyama,et al.  Primary gastrointestinal stromal tumor of the liver: a case report and review of the literature , 2016, Surgical Case Reports.

[11]  Hongwei Zhang,et al.  Clinicopathological feature and prognosis of primary hepatic gastrointestinal stromal tumor , 2016, Cancer medicine.

[12]  Xiukun Li,et al.  Coexisting and possible primary extra-gastrointestinal stromal tumors of the pancreas and liver: A single case report , 2016, Oncology letters.

[13]  M. Bui,et al.  Is DOG1 Immunoreactivity Specific to Gastrointestinal Stromal Tumor? , 2015, Cancer control : journal of the Moffitt Cancer Center.

[14]  Seiichi Hirota,et al.  The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines , 2015, Gastric Cancer.

[15]  Andrew Hopkinson,et al.  Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors , 2014, Stem cells.

[16]  Heikki Joensuu,et al.  Gastrointestinal stromal tumour , 2013, The Lancet.

[17]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[18]  L. Shen,et al.  Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases. , 2012, World journal of gastroenterology.

[19]  S. Hostiuc,et al.  Extrahepatic and Intrahepatic Human Portal Interstitial Cajal Cells , 2011, Anatomical record.

[20]  Xiao-dong Zhou,et al.  Primary gastrointestinal stromal tumor of the liver: a case report. , 2009, World journal of gastroenterology.

[21]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Sciot,et al.  Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An Underestimated Entity , 2008, Clinical Cancer Research.

[23]  L. Popescu,et al.  Interstitial Cajal-like cells in rat mesentery: an ultrastructural and immunohistochemical approach , 2007, Journal of cellular and molecular medicine.

[24]  J. Blay,et al.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[26]  K. Min,et al.  Interstitial Cells of Cajal (ICC) and Gastrointestinal Stromal Tumor (GIST): facts, speculations, and myths , 2006, Journal of cellular and molecular medicine.

[27]  E. Wardelmann,et al.  Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.

[28]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[29]  I. Damjanov,et al.  Primary malignant gastrointestinal stromal tumor of the liver. , 2003, Archives of pathology & laboratory medicine.

[30]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[31]  O. Al-Shboul The Importance of Interstitial Cells of Cajal in the Gastrointestinal Tract , 2013, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[32]  J. Demoulin,et al.  Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. , 2012, American journal of blood research.

[33]  S. Hirota,et al.  Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors. , 2006, Current genomics.